CRECON MEDICAL ASSESSMENT

JP

Series

Series

  • Kobayashi M. Value-based Approach [27]. Introduction to analysis guideline(6) Effect indicator① Thorough explanation of QALY Objectively evaluate medical value. Monthly Medical Information Express. 2020; 2:78-81.(in Japanese)

  • Kobayashi M. Value-based Approach [26]. Introduction to analysis guideline(5) The additional benefit② A benefit of medical fee calculation resembles cost-effectiveness evaluation and non-becomes. Monthly Medical Information Express. 2020; 1:78-81.(in Japanese)

  • Kobayashi M. Value-based Approach [25]. Introduction to analysis guideline(4) The additional benefit A benefit of medical fee calculation resembles cost-effectiveness evaluation and non-becomes. Monthly Medical Information Express. 2019; 11:78-81.(in Japanese)

  • Kobayashi M. Value-based Approach [24]. Introduction to analysis guideline(3) Analysis target group and Comparative technology Corporate strategy and the ability of negotiations tried by comparative setting. Monthly Medical Information Express. 2019; 10:78-81. (in Japanese)

  • Kobayashi M. Value-based Approach [23]. Introduction to analysis guideline(2) The position and cost of analysis. The significance indicating “public medical treatment”. Monthly Medical Information Express. 2019; 9:70-73. (in Japanese)

  • Kobayashi M. Value-based Approach [22]. Introduction to analysis guideline(1) Full-scale introduction of cost-effectiveness evaluation A thorough description of analysis guideline. Monthly Medical Information Express. 2019; 8:66-69. (in Japanese)

  • Kobayashi M. Value-based Approach [21]. Learn the official instruction of cost-effectiveness evaluation! Consistency with the drug price system and strictness to low disclosure items. Monthly Medical Information Express. 2019;6:78-82. (in Japanese)

  • Kobayashi M. Value-based Approach [Special edition]. Learn from scratch! Cost-effectiveness evaluation. About official instruction of Cost-effectiveness evaluation. Monthly Medical Information Express. 2019; 4:30-34. (in Japanese)

  • Kobayashi M. Value-based Approach [20]. The lecture just before official introduction to public healthcare system. Too late to ask about cost-effectiveness evaluation -Can you explain QALY and ICER? Monthly Medical Information Express. 2019; 2:82-84. (in Japanese)

  • Kobayashi M. Value-based Approach [19]. The Japanese version of HTA has come into view. The consistency with existing drug price system is important. Hurry up a training of person in charge! Monthly Medical Information Express. 2018; 12:71-73. (in Japanese)

TOP
費用対効果分析

Cost-effectiveness analysis

To evaluate the cost-effectiveness of pharmaceuticals and medical devices by pharmacoeconomics (medical economic assessment), many specialized technologies and knowledge should be combined. We evaluate the cost-effectiveness of medical technologies using advanced modeling and statistical analysis technologies that we have developed over many years.

  • Cost-effectiveness analysis
  • Decision-making model construction
  • Review of previous studies
  • Systematic review
  • Indirect comparison/
    network meta-analysis
  • Budget impact analysis
    in the introduction of new pharmaceuticals
疾病負担分析

Burden of illness analysis

The socio-economic burden of disease is correlated with the therapeutic value of the disease. However, the estimation of such disease burdens is hardly done. We conduct burden of illness analysis to estimate epidemiological parameters, including the numbers of patients and events, long-term survival rates, and medical expenses.

  • Quantification of a target disease’s
    financial burden
  • Estimation and prediction of the number of patients
  • Estimation of lifetime medical expenses
  • Estimation of expected survival time
リアルワールドデータ

Real-world data/
Patient outcome data analyses

Real-world data, such as medical and receipt data, and patient outcome data are analyzed based on advanced statistical knowledge and technology.

  • Planning of survey/
    Development of protocols
  • Medical data analysis
  • Claims data analysis
  • QOL survey
  • Conjoint analysis/
    Discrete choice experiment (DCE)
  • Exploratory analysis
教育及び各種コンサルティング

Education
and other consulting services

We support in-house educational and enlightenment activities related to pharmacoeconomics (medical economic assessment) and health technology assessment (HTA), and provide consulting services. Furthermore, we provide consulting services based on review and summarization of technology appraisal (TA) by the UK’s National Institute for Health and Clinical Excellence (NICE).

  • Lecture/Workshop
  • Other consulting services
  • Review of NICE TA